Future directions in the evaluation of c-MET-driven malignancies.

about

Current Concepts in Non-Gastrointestinal Stromal Tumor Soft Tissue Sarcomas: A Primer for Radiologists.MET inhibition in lung cancer.

P2860

Q37589535-666A0725-AC7C-4960-BDB1-A9F517F2983F Q38390016-D7B51025-0721-4311-AACE-F4B30577DC8F

P2860

Future directions in the evaluation of c-MET-driven malignancies.

Item

http://www.wikidata.org/entity/Q39405818

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Future directions in the evaluation of c-MET-driven malignancies.

@en

Future directions in the evaluation of c-MET-driven malignancies.

@nl

type

Item

label

Future directions in the evaluation of c-MET-driven malignancies.

@en

Future directions in the evaluation of c-MET-driven malignancies.

@nl

prefLabel

Future directions in the evaluation of c-MET-driven malignancies.

@en

Future directions in the evaluation of c-MET-driven malignancies.

@nl

P1476

Future directions in the evaluation of c-MET-driven malignancies.

@en

P2093

Johann S de Bono

http://www.w3.org/2001/XMLSchema#string

Timothy A Yap

http://www.w3.org/2001/XMLSchema#string

P2860

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

The future of cytotoxic therapy: selective cytotoxicity based on biology is the key

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Met, metastasis, motility and more

Factors underlying sensitivity of cancers to small-molecule kinase inhibitors

Invasive growth: a MET-driven genetic programme for cancer and stem cells

Pharmacodynamic biomarkers for molecular cancer therapeutics

Scatter factor/hepatocyte growth factor is essential for liver development

Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud

P304

S51-60

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1758834011423540

http://www.w3.org/2001/XMLSchema#string

P433

1 Suppl

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51841022

http://www.w3.org/2001/XMLSchema#string

P698

22128288

http://www.w3.org/2001/XMLSchema#string

P932

3225021

http://www.w3.org/2001/XMLSchema#string

Future directions in the evaluation of c-MET-driven malignancies.

about

P2860

P2860

Future directions in the evaluation of c-MET-driven malignancies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932